Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2011-08-19

« New search


V Various

 Substans  Risk  PBT  P  B  T  Volym i DDD
V03 All Other Therapeutic Products
hydroxocobalamin exempt         2 487 250 
calcium acetate exempt         C 1 230 
calcium folinate exempt         26 047 
magnesium carbonate exempt         C 29 303 
protamine sulfate exempt        
rasburicase exempt         30 
deferoxamine insigni-
ficant
1
N.B.
0 0 1
N.B.
flumazenil insigni-
ficant
4 3 0 1
sugammadex insigni-
ficant
4
N.B.
3 0 1
N.B.
deferasirox insigni-
ficant
6 3 0 3
naloxone cannot
be excl
4 3 0 1 C 191 173 
fomepizole cannot
be excl
- - 0 -
calcium polystyrene sulfonate cannot
be excl
- - - -
V08 Contrast Media
gadodiamide insigni-
ficant
3 3 0 0
iomeprol insigni-
ficant
3 3 0 0
iopromide insigni-
ficant
3 3 0 0
gadopentetic acid insigni-
ficant
4 3 0 1
gadoxetic acid insigni-
ficant
4 3 0 1
gadobutrol cannot be excl 4
N.B.
3 0 1
N.B.
amidotrizoic acid cannot
be excl
- - - -
ferumoxsil cannot
be excl
- - - -
gadoteric acid cannot
be excl
- - - -
iobitridol cannot
be excl
- - - -
iodixanol cannot
be excl
- - - -
iohexol cannot
be excl
- - - -
ioxaglic acid cannot
be excl
- - - -
mangafodipir   4 3 0 1